Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tyrosine kinase inhibitors--solid cancers].

K Nakagawa1

  • 1Dept. of 4th Internal Medicine, Kinki University School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 2001
PubMed
Summary

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors like ZD1839 demonstrate significant antitumor effects, challenging previous hypotheses about molecular targeted cancer therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential effects of 1 alpha, 25-dihydroxycholecalciferol and 24R,25-dihydroxycholecalciferol on the proliferation and the differentiated phenotype of rabbit craniofacial chondrocytes in primary culture.

The Journal of Osaka University Dental School·1992
Same author

Adsorption of nafamostat mesilate by hemodialysis membranes.

Artificial organs·1992
Same author

Substrate specificity and distribution of UDP-GalNAc:sialylparagloboside N-acetylgalactosaminyltransferase in the human stomach.

The Biochemical journal·1992
Same author

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1992
Same author

Increased hypothalamic somatostatin mRNA following dexamethasone administration in rats.

Acta endocrinologica·1992
Same author

[A case of jejunal vein thrombosis due to medroxyprogesterone acetate].

Gan to kagaku ryoho. Cancer & chemotherapy·1992

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) are emerging as key molecular agents for cancer treatment.
  • Early trials showed promise for EGFR inhibitor ZD1839 in small cell cancer and BCR-Abl inhibitor STI-571 in chronic myeloid leukemia.

Purpose of the Study:

  • To evaluate the efficacy of the EGFR tyrosine kinase inhibitor ZD1839, particularly in non-small cell lung cancer.
  • To address preliminary hypotheses regarding the mechanism and timeline of TKI effectiveness.

Main Methods:

  • Clinical trials involving ZD1839, focusing on non-small cell lung cancer.
  • Combination chemotherapy including ZD1839 in the pretreatment stage.

Main Results:

  • ZD1839 demonstrated effectiveness in non-small cell lung cancer, a notoriously difficult cancer to treat.
  • Combination therapy with ZD1839 showed clear effectiveness.
  • Tumor reduction effects were observed promptly and demonstrated sustained efficacy, comparable to conventional chemotherapy.

Conclusions:

  • ZD1839 has significantly reshaped the perception of molecular targeted agents in cancer therapy.
  • The study highlights the potent and rapid antitumor activity of EGFR TKIs.

Related Experiment Videos